The Final Results Are In: Pfizer Vaccine Is 95% Effective
The company said it will seek emergency authorization "within days." If approved, Pfizer would likely make history for having the first FDA-approved COVID-19 vaccine.
CNN:
Pfizer And BioNTech Say Their Coronavirus Vaccine Was 95% Effective With No Safety Concerns
A final analysis of the Phase 3 trial of Pfizer's coronavirus vaccine shows it was 95% effective in preventing infections, even in older adults, and caused no serious safety concerns, the company said Wednesday. The company counted 170 cases of coronavirus infection among volunteers who took part in the trial. It said 162 infections were in people who got placebo, or plain saline shots, while eight cases were in participants who got the actual vaccine. That works out to an efficacy of 95%, Pfizer said. The data show Pfizer's initial claim of a better than 90% efficacy -- a claim that stunned and pleased health officials and vaccine developers last week -- holds up. (Fox and Sealy, 11/18)
The New York Times:
New Pfizer Results: Coronavirus Vaccine Is Safe And 95% Effective
If the F.D.A. authorizes the two-dose vaccine, Pfizer has said that it could have up to 50 million doses available by the end of the year, and up to 1.3 billion by the end of next year. However, only about half of its supply will go to the United States this year, or enough for about 12.5 million people — a sliver of the American population of 330 million. Americans will receive the vaccine for free, under a $1.95 billion deal the federal government reached with Pfizer for 100 million doses. (Thomas, 11/18)
ABC News:
Pfizer Vaccine 95% Effective In Final Analysis, Plans To Seek Emergency Authorization 'Within Days'
If the FDA gives the vaccine the green light, Pfizer will likely make history as the first company with an FDA-authorized COVID-19 vaccine. ... It’s not known yet what level of immunity or how long the immunity lasts after receiving the vaccines. Trial volunteers will be followed for two years to answer questions like durability of protection. (Salzman, 11/18)
Bloomberg:
Pfizer, BioNTech Plan Filing As Covid-19 Vaccine Proves 95% Effective
The U.S. drugmaker and partner BioNTech SE said their vaccine protected people of all ages and ethnicities, with no significant safety problems so far in a trial that includes almost 44,000 participants. ... The vaccine’s efficacy in people older than 65 was more than 94%, the companies said. Most people who received the shot tolerated it well. Severe fatigue was seen in 3.7% of volunteers after the second dose in the two-shot regimen, but that was the only severe side effect that occurred in more than 2% of people, according to the analysis. (Langreth, 11/18)
Stat:
Pfizer And BioNTech Covid-19 Vaccine Is 95% Effective, Full Results Show
Pfizer, which did not accept research funding from the federal Operation Warp Speed initiative, has agreed to supply 100 million doses to the U.S. government in exchange for $1.9 billion. The U.S. has the option to buy 400 million more. Moderna received about $1 billion in federal funds to support its vaccine development and has agreed to provide 100 million doses to the U.S. for $1.5 billion. (Garde and Herper, 11/18)
